New and Emerging Treatments

In a series of video interviews filmed with DSUK, Professor Helen Cross OBE (a member of our Advisory Board) discusses the latest treatment developments, including the availability of Epidyolex (cannabidiol), the potential future role of fenfluramine and what we might expect from genetic treatments currently under development. 

In the video below, Professor Cross discusses currently available treatments, the newly-approved Epidyolex (cannabidiol) and another potential new treatment, fenfluramine, which is yet to be approved:

New and emerging treatments for seizures in DS.
Play

In the following video, Professor Cross talks about the differences between cannabidiol and other CBD oil products in relation to the treatment of Dravet Syndrome:

Cannabidiol in the treatment of Dravet Syndrome
Play

In this video, Professor Cross discusses the potential future role for genetic therapies in treating Dravet Syndrome:

Potential new treatments - genetic therapies
Play

In our final video, Professor Cross talks about how new and emerging treatments may affect the future approaches to Dravet Syndrome, including the potential treatment of Dravet comorbidities:

Future approaches to Dravet Syndrome
Play

Parent/Carer Conference presentation

View the presentation that Professor Cross gave at our recent DSUK London 2019 conference, 'New treatment algorithm & emerging treatments for Dravet Syndrome'.

View the presentation